Macrogenics (MGNX) Net Equity Issued and Repurchased (2012 - 2023)
Macrogenics (MGNX) posted quarterly Net Equity Issued and Repurchased of $616000.0 for Q1 2023, down 43.23% quarter-over-quarter from $1.1 million in Q4 2022.
Macrogenics (MGNX) Net Equity Issued and Repurchased (2012 - 2023) Analysis & Trends
Macrogenics (MGNX) has reported Net Equity Issued and Repurchased for 11 consecutive years, with $616000.0 the latest figure, recorded in Q1 2023.
- In Q1 2023, Net Equity Issued and Repurchased changed N/A year-over-year to $616000.0; the TTM figure through Dec 2023 stood at $616000.0 (down 43.23% YoY), while the FY2023 annual figure was $616000.0, down 43.23% from the prior year.
- Net Equity Issued and Repurchased fell to $616000.0 in Q1 2023 per MGNX's latest filing, from $1.1 million in the prior quarter.
- Across five years, Net Equity Issued and Repurchased topped out at $118.7 million in Q1 2019 and bottomed at -$38000.0 in Q4 2020.
- Historically, Net Equity Issued and Repurchased has averaged $51.1 million across 5 years, with a median of $46.8 million in 2020.
- On a YoY basis, Net Equity Issued and Repurchased climbed as much as 73.48% in 2021 and fell as far as 73.48% in 2021.
- Macrogenics' Net Equity Issued and Repurchased stood at $118.7 million in 2019, then plunged by 100.03% to -$38000.0 in 2020, then surged by 51726.32% to $19.6 million in 2021, then plunged by 94.47% to $1.1 million in 2022, then plunged by 43.23% to $616000.0 in 2023.
- Business Quant data shows MGNX's Net Equity Issued and Repurchased at $616000.0 in Q1 2023, $1.1 million in Q4 2022, and $19.6 million in Q3 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 141.90 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Macrogenics | 268.22 Mn | 201.71 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | 616,000.00 |
| Mar 31, 2023 | 616,000.00 |
| Dec 31, 2022 | 1.09 Mn |
| Dec 31, 2022 | 1.09 Mn |
| Sep 30, 2021 | 19.62 Mn |
| Sep 30, 2021 | 19.62 Mn |
| Mar 31, 2021 | 98.20 Mn |
| Mar 31, 2021 | 98.20 Mn |
| Dec 31, 2020 | -38,000.00 |
| Dec 31, 2020 | -38,000.00 |
| Sep 30, 2020 | 73.98 Mn |
| Sep 30, 2020 | 73.98 Mn |
| Jun 30, 2020 | 96.51 Mn |
| Jun 30, 2020 | 96.51 Mn |
| Mar 31, 2019 | 118.66 Mn |
| Mar 31, 2019 | 118.66 Mn |
| Jun 30, 2018 | 259,000.00 |
| Jun 30, 2018 | 259,000.00 |
| Dec 31, 2017 | -50,000.00 |
| Dec 31, 2017 | -50,000.00 |